Navigation Links
PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
Date:1/23/2008

Second Quarter Highlights: - Consolidated service revenue of $238.7 million grows 32% year-over-year - Operating income increases 47.7%, diluted earnings per share grow 25%

- Backlog increases 41% to a record of $1.8 billion

- Net quarterly book-to-burn ratio equates to 1.9

BOSTON, Jan. 23 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) today announced its financial results for the second quarter ended December 31, 2007.

For the three months ended December 31, 2007, PAREXEL's consolidated service revenue increased 32.2% to a record $238.7 million, compared with $180.5 million in the prior year period. The Company reported operating income of $20.5 million, or 8.6% of service revenue, versus operating income of $13.9 million, or 7.7% of service revenue, in the comparable quarter of the prior year. Net income for the quarter totaled $11.5 million, or $0.40 per diluted share, compared with net income of approximately $9.1 million, or $0.32 per diluted share, for the quarter ended December 31, 2006, representing earnings per share growth of 25%.

On a segment basis, consolidated service revenue for the second quarter of Fiscal Year 2008 was $182.7 million in Clinical Research Services (CRS), $32.5 million in PAREXEL Consulting and Medical Communications Services (PCMS), and $23.4 million in Perceptive Informatics, Inc.

PAREXEL's backlog increased approximately 41% year-over-year, and 13% sequentially, to $1.778 billion at the end of the December quarter. As of September 30, 2007, PAREXEL's backlog totaled $1.570 billion. Adding the December quarter's gross new business wins of $486.8 million to that amount, and subtracting $238.7 million
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
2. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
3. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
4. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
7. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
8. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
9. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
10. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
11. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2008)... money on home medical and wellness .... 15 /- VidaCura, Incorporated,today...lness store,VidaCura.com. VidaCura.com provides a...ess products along with information and insurance,...ove their health and,learn how they can manage med...
(Date:10/15/2008)... and business development flexibility, TSX Exchan...tCall/ - Resverlogix Corp.,("Resverlogix") (TSX:RV...lion or approximately 60% of its remaining USD$17.... and CEO of Resverlogix stated, "The,economic envi...companies,around the globe. This action limits our...
(Date:10/15/2008)...ael, October 15 /-,Simbionix USA Corp... Series,C round of growth capital financing led by...investor Early Stage Partners and other existing,s...ho served as the,company,s investment bankers. The...e already rapid growth of its medical simulation t...
(Date:10/15/2008)...e-FirstCall/ -- Cryo-Cell,International, Inc. (OTC...,world,s largest and most established family cord ... quarter and nine months ended August 31,2008., ...pproximately $4.5,million compared to approximatel...Company reported a net loss in the third quarter 2...
Breaking Biology Technology:In the Midst of International Economic Crisis, VidaCura Offers a Helping Hand to Those Without Insurance 2Resverlogix Eliminates Sixty Percent of Remaining Debt 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 2Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 3Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 4Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 5Cryo-Cell International, Inc. Reports Third Quarter 2008 Results 6
...San Diego - A company that uses Medical College o...logical expertise has been awarded $2.5 million fo...nia. , ,The company, Nanogen, Inc., said the res...ars, would enable it to develop improved molecular...d demonstrate the performance of this new molecula...
... Madison, Wis. - It,s not surprising that Gov. J...ill at odds over how the state,s latest budget wil...Doyle thinks he saved K-12 districts from cuts wit...yle abused his veto power and put more spending on...r public education appears destined never to be se...
...MILWAUKEE -- Marshall & Ilsley Corp . announced ...th Plansmith Corp . of Schaumburg, Ill., to expan... ,With the partnership, M&I will use Plansmith,s C...ware to assist financial institutions in their pro...,M&I began offering a planning assistance program ...
... An entry to a consumer,s house in any foreign lan...re was this product born? What,s its true national...today? What,s the bearer,s nation done for my nati...o secret that consumers all over the world are far...o. They clearly support or oppose their own countr...
Other Biology Technology:Before deciding how to pay for K-12 schools, let's determine what to buy 2Before deciding how to pay for K-12 schools, let's determine what to buy 3Why are brands culturally profiled? 2Why are brands culturally profiled? 3
(Date:10/14/2008)..., The gecko,s amazing ability to stick to surfaces...o manufacture materials that mimic the special sur...o,s ability to stick so well is a forest of pillar... gecko,s foot. Because there are so many pillars s...face the gecko is walking on by a molecular force ...
(Date:10/14/2008)... Infection is the leading cause of infant deaths ...ker, pre-term infants. Current diagnostic tests ca...ow identified potential biomarkers in the blood th...n and type of microbe. , The circulatory system...tephen Kingsmore and colleagues analyzed plasma sa...
(Date:10/14/2008)...tics researchers have identified two novel gene lo... they continue to reveal pieces of the complicated...expect to improve predictive tests and devise prev... of the biology of type 1 diabetes and better unde...ill be able to develop better diagnostic tests tha...
(Date:10/14/2008)...ADELPHIAThe National Institutes of Health has awar...an scientists, including The Academy of Natural Sc...nd biofuels technology from marine mollusks for de...concentrated in the Philippine archipelago, whose ... mollusk speciesabout a fifth of all the known spe...
Breaking Biology News(10 mins):Researchers continue to find genes for type 1 diabetes 2Academy participates in project to discover drugs, biofuels in tropical seas 2Perr 26Knight Announces Discounted Fee Schedule for Access to Its Online Database of Commercial Lines Competitor Filings 17456 1Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 17452 1Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous 28TM 29 Bio engineered R stent 28TM 29 17452 2Orchard Supply Hardware Partners With Canary Foundation 17448 1Orchard Supply Hardware Partners With Canary Foundation 17448 2Orchard Supply Hardware Partners With Canary Foundation 17448 3Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 1Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 2Elusys Anthim 28TM 29 Dramatically Improves Survival of Animals Treated After Active Anthrax Infection 4776 3
...ngton University in St. Louis have made an importa...ells take to silence unwanted or extra genes using...ossible to see where, and how, the events in the p...ving, as the old saying goes. , Craig Pikaa...ogy in Arts & Sciences and his collaborators h...
...lose oneself" in an experience? Many theoretical m...at awareness is dependent on the mediation of area...f-aware "observer" network ?in the human brain. , ...el of the Weizmann Institute,s Neurobiology Depart...uestion ?by scanning the brains of volunteers perf...
...f bacteria -- the way they get a foothold in plant...cording to research published this week by Michiga...he bacterial pathogen Pseudomonas syringae, better...e pathogen reared its speckled head in tomatoes, c...describes using P. syringae in the laboratory plan...
... that dynamic regions of the human genome -- "hots...e potentially involved in the rapid evolution of m...re genetically determined. , Now, an international... and an associate professor from Arizona State Uni...es, which has implications for the understanding o...
Other Biology News:Pathway toward gene silencing described in plants 2Pathway toward gene silencing described in plants 3Pathway toward gene silencing described in plants 4Lost in thought: Brain research 2Chimpanzee study reveals genome variation hotspots 2
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis.
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications).
Biology Products: